Acerus Signs License Agreement to Nasal Technology with University of Texas at Austin

Acerus Pharmaceuticals Corporation announced that it has signed a patent license agreement with the University of Texas at Austin for technology related to the nasal administration of testosterone. The newly patented, aqueous-based, nasal delivery technology was developed by Robert Josephs, a UT Austin Professor of Clinical and Social Psychology, and Craig Herman, a Doctor of Pharmacy at MedCara Pharmaceuticals in Conrad, Iowa. Under the PLA, Acerus has licensed worldwide exclusive rights to this technology in all applicable fields.

“We are pleased to have partnered with UT Austin and Professor Josephs for the development of this technology,” said Ed Gudaitis, President & CEO of Acerus. We expect that this new technology will allow us to develop therapeutic options that will complement our existing nasal technology. Acerus’ expertise in the formulation and development of nasally delivered active pharmaceutical ingredients, and more particularly testosterone, should enable Acerus to make this new technology a success.”